<?xml version='1.0' encoding='utf-8'?>
<document id="27604990"><sentence text="Application of a &quot;Fit for Purpose&quot; PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide."><entity charOffset="95-107" id="DDI-PubMed.27604990.s1.e0" text="Enzalutamide" /></sentence><sentence text="Oncology therapy typically involves drug combinations since monotherapy seldom provides the desired outcome" /><sentence text=" But combination therapy presents the potential for drug-drug interactions (DDIs)" /><sentence text=" Due to the narrow window between therapeutic concentrations and onset of toxicity often observed with oncology therapeutics, managing DDIs with combination therapy in cancer is critical" /><sentence text=" Physiologically based pharmacokinetic (PBPK) modeling can be effectively used for predicting DDIs and guiding dose-selection, but requires development of PBPK models of cancer drugs" /><sentence text=" Among various types of cancer, metastatic prostate cancer is an area of high unmet medical need with minimal therapeutic options" /><sentence text=" Recently, enzalutamide was approved for treatment of metastatic prostate cancer and is often dosed as a combination in clinical practice"><entity charOffset="11-23" id="DDI-PubMed.27604990.s7.e0" text="enzalutamide" /></sentence><sentence text=" Enzalutamide is a potent CYP3A inducer and a model-based approach to guide dose-selection for enzalutamide combinations that are CYP3A substrates is needed"><entity charOffset="1-13" id="DDI-PubMed.27604990.s8.e0" text="Enzalutamide" /><entity charOffset="95-107" id="DDI-PubMed.27604990.s8.e1" text="enzalutamide" /><pair ddi="false" e1="DDI-PubMed.27604990.s8.e0" e2="DDI-PubMed.27604990.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27604990.s8.e0" e2="DDI-PubMed.27604990.s8.e1" /></sentence><sentence text="" /><sentence text="A &quot;fit for purpose&quot; PBPK model of enzalutamide was developed to illustrate the CYP3A4 induction potential, understand the kinetics of de-induction of CYP3A4 following cessation of enzalutamide dosing and guide dose-selection of a co-administered CYP3A substrate"><entity charOffset="34-46" id="DDI-PubMed.27604990.s10.e0" text="enzalutamide" /><entity charOffset="180-192" id="DDI-PubMed.27604990.s10.e1" text="enzalutamide" /><pair ddi="false" e1="DDI-PubMed.27604990.s10.e0" e2="DDI-PubMed.27604990.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27604990.s10.e0" e2="DDI-PubMed.27604990.s10.e1" /></sentence><sentence text="" /><sentence text="The population-based simulator, Simcyp, was used for model building purposes" /><sentence text=" Model input parameters were obtained from public information, primarily from the FDA summaries" /><sentence text="" /><sentence text="The simulated concentration time profiles of enzalutamide in healthy male subjects were comparable to observed profiles in male patients"><entity charOffset="45-57" id="DDI-PubMed.27604990.s15.e0" text="enzalutamide" /></sentence><sentence text=" Model predicted enzalutamide pharmacokinetic (PK) parameters, i"><entity charOffset="17-29" id="DDI-PubMed.27604990.s16.e0" text="enzalutamide" /></sentence><sentence text="e" /><sentence text=" AUC, Cmax and half-life were within 1" /><sentence text="5-fold of observed results obtained from two reported studies, supporting verification of the PBPK model" /><sentence text=" Model application was demonstrated by simulating a drug-drug interaction between enzalutamide and midazolam, a sensitive CYP3A4 substrate"><entity charOffset="82-94" id="DDI-PubMed.27604990.s20.e0" text="enzalutamide" /><entity charOffset="99-108" id="DDI-PubMed.27604990.s20.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.27604990.s20.e0" e2="DDI-PubMed.27604990.s20.e0" /><pair ddi="false" e1="DDI-PubMed.27604990.s20.e0" e2="DDI-PubMed.27604990.s20.e1" /></sentence><sentence text=" Based on simulations, the midazolam AUC ratio ranged from 0" /><sentence text="06 to 0" /><sentence text="16 and was comparable to the observed ratio of 0" /><sentence text="14" /><sentence text=" Based on modeling, upon cessation of enzalutamide dosing, it is predicted that at least 8 weeks are needed to re-attain baseline CYP3A4 activity"><entity charOffset="38-50" id="DDI-PubMed.27604990.s25.e0" text="enzalutamide" /></sentence><sentence text=" Based on PBPK modeling, dose adjustment of up to 3-fold for a co-administered CYP3A substrate was shown to re-attain baseline exposure" /><sentence text="" /><sentence text="A &quot;fit for purpose&quot; PBPK model of enzalutamide was successfully developed using public information that recapitulated it's observed pharmacokinetics, CYP3A4 induction potential and the potential need for dose-adjustment of co-administered CYP3A substrates"><entity charOffset="34-46" id="DDI-PubMed.27604990.s28.e0" text="enzalutamide" /></sentence><sentence text="" /></document>